On Wednesday, the same day McCain's brain cancer diagnosis was publicly revealed, a paper was published in the journal Science Translational Medicine discussing a CAR-T approach to treating glioblastoma.
As many as two-thirds of glioblastoma patients don't respond to a central class of treatments due to a nifty DNA repair mechanism known as MGMT. DelMar Pharmaceuticals has a workaround that it hopes can extend the lives of patients in a meaningful way.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.